PIMECROLIMUS

Post-LOE

pimecrolimus

Ichnos Glenmark Innovation

ANDATOPICALCREAM

Approved

Aug 2019

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

PIMECROLIMUS (pimecrolimus) by Ichnos Glenmark Innovation is calcineurin inhibitors [moa]. Approved for calcineurin inhibitor immunosuppressant [epc]. First approved in 2019.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

Calcineurin Inhibitors

Pharmacologic Class:

Calcineurin Inhibitor Immunosuppressant

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (20)

NCT00946478N/ACompleted

Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema

Started Oct 2009

40 enrolled

Atopic Dermatitis

NCT00403559Phase 2Completed

A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis

Started May 2007

113 enrolled

Seborrheic Dermatitis

NCT00507832Phase 2Completed

Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease

Started Apr 2007

30 enrolled

Prurigo Nodularis

NCT00810862Phase 4Terminated

Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children

Started Nov 2006

18 enrolled

Atopic Dermatitis

NCT00393263Phase 2Completed

Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus

Started Oct 2006

38 enrolled

Lichen Sclerosus

Worked on PIMECROLIMUS at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.